Viatris agreed to acquire Pacira BioSciences in a deal valued at about $1.65 billion, acquiring the company’s established pain portfolio including Exparel and Zilretta. The transaction is priced at $36.50 per share in cash and would give Viatris two marketed non-opioid analgesics with combined first-half 2026 revenue disclosed at $350.5 million. The acquisition underscores continued consolidation around commercial products with clear revenue bases as biopharma pursues steadier cash flows amid financing constraints. For Pacira, it provides a clear path to scale commercialization through a larger distribution platform. The market implication is that “post-patent cliff” growth strategies are still being pursued through asset tuck-ins—rather than solely relying on new molecular entities—particularly in pain where differentiation can be anchored to clinical use settings and reimbursement pathways.